

OFF-NOTE BLOCKING SENSORY ORGANIC COMPOUNDS

5

TECHNICAL FIELD

Disclosed are compounds that allow to mask or block undesirable off-notes in consumables and the method of blocking off-notes employing said compounds in consumables.

10

SUMMARY

Provided are the following:

- (1) An off-note blocking compound selected from one or more of 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid, 4-(2,2,3-trimethylcyclopentyl)butanoic acid, 4-(2,2,6-trimethylcyclohexyl)butanoic acid, 3-(2,2,6-trimethylcyclohexyl)propanoic acid, 2-(3,4-dimethylcyclohexyl)acetic acid, 2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid, 1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid; (E)-3-(1-(2,2,3-trimethylcyclopent-3-enyl)cyclopropyl)acrylic acid, (E)-4-(2,2,3-trimethylcyclohex-3-enyl)but-2-enoic acid, (E)-4-(2,2,3-trimethylcyclopentyl)but-3-enoic acid, (E)-4-(2,2,3-trimethylcyclopentyl)but-2-enoic acid, 1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid, 2,2-dimethyl-4-(2,2,3-trimethylcyclopentyl)butanoic acid, 2-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)-1-methylcyclopropanecarboxylic acid, 2-(1-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)propanoic acid, 2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid, 3,3-dimethyl-4-(2,2,3-trimethylcyclopentyl)butanoic acid, and 4-(1-methylbicyclo[3.1.0]hexan-2-yl)butanoic acid, (E)-1-(2-(1-methylbicyclo[3.1.0]hexan-2-yl)vinyl)cyclopropanecarboxylic acid, (E)-1-(2-(7-methylspiro[2.4]heptan-4-yl)vinyl)cyclopropanecarboxylic acid, (E)-4-(1-methylbicyclo[3.1.0]hexan-2-yl)but-3-enoic acid, (E)-4-(7-methylspiro[2.4]hept-6-en-4-yl)but-2-enoic acid, (E)-4-(7-methylspiro[2.4]heptan-4-yl)but-3-enoic acid, (E)-4-(7-methylspiro[2.4]heptan-4-yl)but-2-enoic acid, (E)-4-(8-methylspiro[2.5]oct-7-en-4-yl)but-2-enoic acid, 1-(2-(7-methylspiro[2.4]heptan-4-yl)ethyl)cyclopropanecarboxylic acid, 2-((6,7-dimethylspiro[2.4]heptan-4-yl)methyl)-1-methylcyclopropanecarboxylic acid, 2-(1-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)propanoic acid,

35

2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid, 2-(1-((7-methylspiro[2.4]heptan-4-yl)methyl)cyclopropyl)acetic acid, and 4-(7-methylspiro[2.4]heptan-4-yl)butanoic acid.

- 5 (2) The off-note blocking compound as described herein, including under (1),
selected from one or more of 4-(2,2,3-trimethylcyclopentyl)butanoic acid, 4-
(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid, 4-(2,2,6-
trimethylcyclohexyl)butanoic acid, 3-(2,2,6-trimethylcyclohexyl)propanoic
acid, 4-propylcyclohexanecarboxylic acid, and 2-(3,4-dimethylcyclohexyl)acetic
10 acid.

- (3) A flavor composition comprising an off-note providing consumable ingredient and
one or more of the off-note blocking compounds listed herein, including under (1) and
15 (2).

- (4) A consumable comprising
a) one or more ingredient in a concentration sufficient to provide an off-
note, and
b) one or more of the off-note blocking compounds listed herein,
20 including under (1) and (2).

- (5) A consumable as herein described, including under (4), wherein the one or more
off-note providing ingredient is selected from one or more of sweetener, artificial
sweetener, beverage, chewing gum, nutraceutical, and pharmaceutical.
25

- (6) A consumable of as herein described, including under (4), wherein the one or
more off-note providing ingredient is an artificial sweetener selected from one or
more of aspartame, acesulfame K, saccharin, sucralose, and sodium cyclamate.

- 30 (7) A consumable as herein described, including under (4), wherein the one or more
off-note providing ingredient comprises a sweetener selected from one or more of
stevioside, swingle extract, glycyrrhizin, perillartine, naringin dihydrochalcone,
neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and
rebaudioside A
35

(8) A consumable as herein described, including under (4), wherein the off-note providing ingredient comprises a consumable selected from one or more of cocoa, coffee, caffeine, theobromine, diketopiperazines, vitamins, amino acids, vitamin B, casein, soy protein, ibuprofen, salicylic acid, glucoronolactone, acetaminophen, dextromethorphan, naringin, taurin, macrolide (including bioxin and erythromycin), paracetamol, acetylsalicylic acid, cimetidine, ranitidine, amoxicillin, acetaminophen, cephalosporines, quassia, propylene glycol, triacetin, salts of potassium, salts of zinc, loperamide, limonin, flavonoides, isoflavones (including genistein and diadzein), polyphenol (including catechin and epicatechin), mint oil, D-menthol, hydrolysed vegetable protein, bitter peptides, preservatives (including benzoic acid, potassium sorbate, polysorbate 80, sodium and potassium lactate, sodium benzoate), citric acid, quinine, urea (contained in chewing gums), essential oils (including thyme, sage, basil, mint), Maillard reaction products (including cyclic amines made from pyrrolidine/glucose, alanine/xylose, proline/sucrose or alanine/xylose, for example diketopiperazines), beer, hops, humulone, trans-isohumulone, lupulone, and hulupone.

(10) A method of blocking off-notes in a consumable comprising admixing with the consumable (a) one or more off-note providing ingredient in a concentration sufficient to provide an off-note, and (b) one or more compounds of the off-note blocking compounds listed herein, including under (1) and (2).

(11) A method as herein described, including under (10), wherein the one or more off-note providing ingredient is selected from the group consisting of sweetener, artificial sweetener, beverage, chewing gum, nutraceutical, and pharmaceutical.

(12) A method as herein described, including under (10) and (11), wherein the off-note providing ingredient comprises one or more artificial sweetener selected from aspartame, acesulfame K, saccharin, sucralose, and sodium cyclamate.


(13) A method of as herein described, including under (10) to (12), wherein the off-note providing ingredient comprises one or more sweetener selected from stevioside, swingle extract, glycyrrhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A.

- (14) A method as herein described, including under (10) to (13), wherein the off-note providing ingredient comprises one or more consumable selected from cocoa, coffee, caffeine, theobromine, diketopiperazines, vitamins, amino acids, vitamin B, casein, soy protein, ibuprofen, salicylic acid, glucoronolactone, acetaminophen,
- 5 dextromethorphan, naringin, taurin, macrolide (including bioxin and erythromycin), paracetamol, acetosalicylic acid, cimetidine, ranitidine, amoxicillin, acetaminophen, cephalosporines, quassia, propylene glycol, triacetin, salts of potassium, salts of zinc, loperamide, limonin, flavonoides, isoflavones (including genistein and diadzein), polyphenol (including catechin and epicatechin), mint oil, D-menthol, hydrolysed
- 10 vegetable protein, bitter peptides, preservatives (including benzoic acid, potassium sorbate, polysorbate 80, sodium and potassium lactate, sodium benzoate), citric acid, quinine, urea (contained in chewing gums), essential oils (including thyme, sage, basil, mint), Maillard reaction products (including cyclic amines made from pyrrolidine/glucose, alanine/xylose, proline/sucrose or alanine/xylose, for example
- 15 diketopiperazines), beer, hops, humulone, trans-isohumulone, lupulone, and hulupone.

DETAILED DESCRIPTION


- 20 The off-note blocking compounds provided herein include the following off-note blocking compounds: 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid, 4-(2,2,3-trimethylcyclopentyl)butanoic acid, 4-(2,2,6-trimethylcyclohexyl)butanoic acid, 3-(2,2,6-trimethylcyclohexyl)propanoic acid, 2-(3,4-dimethylcyclohexyl)acetic acid, 2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid, and 1-methyl-2-((1,2,2-
- 25 trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid.

The chemical structures of these compounds are indicated below:




4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid


- (including (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid), and (Z)-4-(2,2,3-
- 30 trimethylcyclopent-3-enyl)but-2-enoic acid)




4-(2,2,3-trimethylcyclopentyl)butanoic acid



4-(2,2,6-trimethylcyclohexyl)butanoic acid




3-(2,2,6-trimethylcyclohexyl)propanoic acid




5

2-(3,4-dimethylcyclohexyl)acetic acid



2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid



10

1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid.

Without wishing to be bound by theory, the presence of 1 to 3 cyclopropyl groups at the 5-ring or 6-ring part of the off-note blocking compound and/or the linker linking the ring to the acid group tends to increase the off-note blocking activity.

15 According to certain embodiments, these compounds are particularly useful for blocking the bitter off-note blocking activity. Furthermore, 5-ring structures (cyclopentane) tend to have higher activities than the related 6-ring structures (cyclohexane).

20 According to certain embodiments, the following groups of compounds may also be useful for off-note blocking in consumables:



One or more compound selected from (E)-3-(1-(2,2,3-trimethylcyclopent-3-enyl)cyclopropyl)acrylic acid, (E)-4-(2,2,3-trimethylcyclohex-3-enyl)but-2-enoic acid, (E)-4-(2,2,3-trimethylcyclopentyl)but-3-enoic acid, (E)-4-(2,2,3-trimethylcyclopentyl)but-2-enoic acid, 1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-

25

- 3-yl)methyl)cyclopropanecarboxylic acid, 2,2-dimethyl-4-(2,2,3-trimethylcyclopentyl)butanoic acid, 2-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)-1-methylcyclopropanecarboxylic acid, 2-(1-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)propanoic acid, 2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid, 3,3-dimethyl-4-(2,2,3-trimethylcyclopentyl)butanoic acid, and 4-(1-methylbicyclo[3.1.0]hexan-2-yl)butanoic acid.

The chemical structures of these compounds are shown below.

Structure	Name
	(E)-4-(2,2,3-trimethylcyclopentyl)but-3-enoic acid
	(E)-4-(2,2,3-trimethylcyclopentyl)but-2-enoic acid
	(E)-4-(2,2,3-trimethylcyclohex-3-enyl)but-2-enoic acid
	2,2-dimethyl-4-(2,2,3-trimethylcyclopentyl)butanoic acid
	3,3-dimethyl-4-(2,2,3-trimethylcyclopentyl)butanoic acid
	4-(1-methylbicyclo[3.1.0]hexan-2-yl)butanoic acid
	1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid
	2-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)-1-methylcyclopropanecarboxylic acid
	2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid





	2-(1-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)propanoic acid
	(E)-3-(1-(2,2,3-trimethylcyclopent-3-enyl)cyclopropyl)acrylic acid










According to further embodiments, the following group of compounds may also be useful in off-note blocking in consumables:

- (E)-1-(2-(1-methylbicyclo[3.1.0]hexan-2-yl)vinyl)cyclopropanecarboxylic acid, (E)-1-
5 (2-(7-methylspiro[2.4]heptan-4-yl)vinyl)cyclopropanecarboxylic acid, (E)-4-(1-methylbicyclo[3.1.0]hexan-2-yl)but-3-enoic acid, (E)-4-(7-methylspiro[2.4]hept-6-en-4-yl)but-2-enoic acid, (E)-4-(7-methylspiro[2.4]heptan-4-yl)but-3-enoic acid, (E)-4-(7-methylspiro[2.4]heptan-4-yl)but-2-enoic acid, (E)-4-(8-methylspiro[2.5]oct-7-en-4-yl)but-2-enoic acid, 1-(2-(7-methylspiro[2.4]heptan-4-yl)ethyl)cyclopropanecarboxylic
10 acid, 2-((6,7-dimethylspiro[2.4]heptan-4-yl)methyl)-1-methylcyclopropanecarboxylic acid, 2-(1-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)propanoic acid, 2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid, 2-(1-((7-methylspiro[2.4]heptan-4-yl)methyl)cyclopropyl)acetic acid, and 4-(7-methylspiro[2.4]heptan-4-yl)butanoic acid.

15

The chemical structures of these compounds are shown below.


Structure	name
	(E)-4-(7-methylspiro[2.4]hept-6-en-4-yl)but-2-enoic acid
	(E)-4-(8-methylspiro[2.5]oct-7-en-4-yl)but-2-enoic acid
	4-(7-methylspiro[2.4]heptan-4-yl)butanoic acid
	2-(1-((7-methylspiro[2.4]heptan-4-yl)methyl)cyclopropyl)acetic acid

	2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid
	2-((6,7-dimethylspiro[2.4]heptan-4-yl)methyl)-1-methylcyclopropanecarboxylic acid
	1-(2-(7-methylspiro[2.4]heptan-4-yl)ethyl)cyclopropanecarboxylic acid
	(E)-1-(2-(7-methylspiro[2.4]heptan-4-yl)vinyl)cyclopropanecarboxylic acid
	2-(1-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)propanoic acid
	(E)-4-(7-methylspiro[2.4]heptan-4-yl)but-3-enoic acid
	(E)-4-(7-methylspiro[2.4]heptan-4-yl)but-2-enoic acid
	(E)-4-(1-methylbicyclo[3.1.0]hexan-2-yl)but-3-enoic acid
	(E)-1-(2-(1-methylbicyclo[3.1.0]hexan-2-yl)vinyl)cyclopropanecarboxylic acid

Most compounds can be synthesized easily by methods well known in the art, or as indicated below or in the examples herein.


5 Synthesis of 2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid:

2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid can be synthesized in one step from 2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanal analogously to the synthesis pathway as described by Ochiai et al. 1989, Journal of Organic Chemistry, 54(20), 4832-40.



Synthesis of 2-(3,4-dimethylcyclohexyl)acetic acid:


2-(3,4-dimethylcyclohexyl)acetic acid can be synthesized from 2-(3,4-dimethylphenyl)acetic acid as indicated below using hydrogen and platinumoxide (H_2/PtO_2) as catalyst analogously to the synthesis pathway as described by Gault et al. (1958), *Compt. rend.*, 246, 123-5.



10 Synthesis of 1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid:

The compound can be synthesized starting from (1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)methanol (aka Javanol®) using Ruthenium(III) chloride and sodium periodate analogously to the synthesis pathway as described by Hart et al. 2003, *Journal of Organic Chemistry* 68(1), 187-190.

15 Javanol® is commercially available from Givaudan, Vernier, Switzerland.



The synthesis of further compounds is described in examples 2a to 2d herein below.

20 The remainder of compounds can be synthesized analogously, as will be apparent to the skilled person.

A receptor screen with concentration-response analysis was performed and from results inhibitory concentration (IC) IC_{50} values can be calculated by nonlinear

regression using the function $f(x) = (a-d)/(1+(x/C)^{nh}) + d$; with a = minimum signal, d = maximum signal, nh = hill coefficient, $C = IC_{50}$. and x = concentration of antagonist. IC_{50} is the molar concentration of an antagonist which produces 50% of the maximum possible inhibitory response for that antagonist. A more potent antagonist will have a lower IC_{50} value.

Most of the off-note blocking compounds disclosed herein, and in particular, for example, 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid, 4-(2,2,3-trimethylcyclopentyl)butanoic acid, 4-(2,2,6-trimethylcyclohexyl)butanoic acid, 3-(2,2,6-trimethylcyclohexyl)propanoic acid, 2-(3,4-dimethylcyclohexyl)acetic acid, 2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid, and 1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid, have an IC_{50} in the range of about 0.1 to 20 micromolar when tested with the TAS2R44 bitter taste receptor.

For most food applications, a low IC_{50} [micro molar] of 0.05 to 10 is desirable, however, IC_{50} of 10 to 25 are still good and above 25 may also still acceptable depending on the application.

Various food ingredients (including ingredients naturally contained in food or additives admixed to food including flavor ingredients) provide undesirable off-notes. Particularly undesirable off-notes are the bitter off-notes, metallic off-notes, lingering, licorice-type and astringent off-notes. The term off-note refers to an unpleasant after taste that develops over time after consumption of consumables.

Other particular examples are the bitter and/or metallic and/or astringent and/or "artificial" off-notes and/or a cloyingly sweet off-note (as opposed to the "cleaner" taste of sugar) that are associated with a number of artificial sweeteners including aspartame, Ace K, saccharin, sucralose, and sodium cyclamate. Sometimes these off-notes of artificial sweeteners are described collectively as bitter off-notes.

Further examples of off-note providing ingredients are naturally occurring sweeteners including stevioside, swingle extract, glycyrrhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, and rebaudioside A

Still further examples of off-note providing ingredients include cocoa, coffee, caffeine, theobromine, diketopiperazines, vitamins, amino acids, vitamin B, casein, soy protein, ibuprofen, salicylic acid, glucoronolactone, acetaminophen, dextromethorphan, naringin, taurin, macrolide (including bioxin and erythromycin),
 5 paracetamol, acetosalicylic acid, cimetidine, ranitidine, amoxicillin, acetaminophen, cephalosporines, quassia, propylene glycol, triacetin, potassium, zinc, loperamide, limonin, flavonoides, isoflavones (including genistein and diadzein), polyphenol (including catechin and epicatechin), mint oil, D-menthol, hydrolysed vegetable protein, bitter peptides, preservatives (including benzoic acid, potassium sorbate,
 10 polysorbate 80, sodium and potassium lactate, sodium benzoate), citric acid, quinine, urea (contained in chewing gums), essential oils (including thyme, sage, basil, mint), Maillard reaction products (including cyclic amines made from pyrrolidine/glucose, alanine/xylose, proline/sucrose or alanine/xylose, for example diketopiperazines), beer, hops, humulone, trans-isohumulone, lupulone, hulupone.

15 The addition of off-note blockers will block or mask the off-notes and make them less apparent or unnoticeable. Artificial sweeteners will thereby lose their bitter/metallic taste and/or their cloyingly sweet lingering sweetness and instead taste more like actual sugar (sucrose).

20 Aspartame is the name for aspartyl-phenylalanine-1-methyl ester, a dipeptide. It is known under various trademark names including Equal®, and Canderel®. In the European Union, it is also known under the E number (additive code) E951.

25 Acesulfame potassium (AceK) is the potassium salt of 6-methyl-1,2,3-oxathiazine-4(3H)-one 2,2-dioxide, an N-sulfonylamide. It is also known as Acesulfame K or AceK, or under various trademark names including Sunett® and Sweet One®. In the European Union it is also known under the E number (additive code) E950.

30 Saccharin is the Na salt of 1,2-Benzisothiazol-3(2H)-one, 1,1-dioxide, an N-sulfonamide. It is also known under various trademark names including Sweet'n low®.

35 Sucralose is the name for 6-dichloro-1,6-dideoxy-β-D-fructo-furanosyl 4-chloro-4-deoxy-α-D-galactopyranoside, which is a chlorodeoxysugar. It is also known by the trade name Splenda®. In the European Union, it is also known under the E number

(additive code) E955. Sucralose has an off-note (also designated "aftertaste") that is a lingering liquorice-like off-note sometimes also described as bitter.

5 The off-note blockers can be added to consumables to block the undesirable off-notes of ingredients present in said consumables or added to such consumables.

10 Flavor compositions for addition to consumables can be formed that provide the off-note blockers and an off-note providing ingredient for addition to consumables, and optionally food grade excipients. Alternatively, the off note blockers can be directly added to consumables.

15 In particular, the off-note blockers can be added to flavor compositions or directly to consumables to block the undesirable off-notes of off-note providing ingredients including natural and artificial sweeteners added to such consumables.

Consumables include all food products, food additives, nutraceuticals, pharmaceuticals and any product placed in the mouth including chewing gum, oral care products, and oral hygiene products including but not limited to, cereal products, rice products, tapioca products, sago products, baker's products, biscuit products, 20 pastry products, bread products, confectionery products, desert products, gums, chewing gums, mouthwash, dental floss, flavored or flavor-coated straws, flavor or flavor-coated food/beverage containers, chocolates, ices, honey products, treacle products, yeast products, baking-powder, salt and spice products, savory products, mustard products, vinegar products, sauces (condiments), tobacco products, cigars, 25 cigarettes, processed foods, cooked fruits and vegetable products, meat and meat products, jellies, jams, fruit sauces, egg products, milk and dairy products, yoghurts, cheese products, butter and butter substitute products, milk substitute products, soy products, edible oils and fat products, medicaments, beverages, carbonated beverages, alcoholic drinks, beers, soft drinks, mineral and aerated waters and other 30 non-alcoholic drinks, fruit drinks, fruit juices, coffee, artificial coffee, tea, cocoa, including forms requiring reconstitution, food extracts, plant extracts, meat extracts, condiments, nutraceuticals, gelatins, pharmaceutical and non-pharmaceutical gums, tablets, lozenges, drops, emulsions, elixirs, syrups and other preparations for making beverages, and combinations thereof.

35

For example, in consumables containing potassium, the off-note blocker may be added to suppress the bitterness and the metallic off-note associated with potassium.

5 In coffee and cocoa products, the off-note blocker may be added to suppress the bitterness associated with caffeine, theobromine, and/or diketopiperazines present in said products.

10 In cheese products, in particular in enzyme-modified cheese products, the off-note blocker may be added to suppress the bitterness associated with bitter peptides present in said cheese products.

15 In soy products, the off-note blocker may be added to suppress the bitterness and beany off-notes associated with peptides, isoflavones such as genistein and diadzein present in said products.

In HVP (hydrolysed vegetable protein) products, the off-note blocker may be added to suppress the bitterness associated with bitter peptides present in said products.

20 In functional ingredients used in fortified foods, the off-note blocker may be added to suppress the bitterness associated with vitamins and amino acids present in said products.

25 In pharmaceuticals, the off-note blocker may be added to suppress the bitterness associated with actives or bitter additives present in said products.

In consumables containing solvents, the off-note blocker may be added to suppress the bitterness associated with propylene glycol, triacetin, or ethanol present in said products.

30 In citrus products, the off-note blocker may be added to suppress the bitterness associated with naringin present in said products.

35 In nutraceuticals and herb medicines, the off-note blocker may be added to suppress the bitterness associated with actives or additives present in said products.

In consumables containing polyphenols such as catechin and epicatechin, the off-note blocker may be added to suppress the bitterness associated with these ingredients.

- 5 In consumables containing preservatives such as potassium sorbate, polysorbate 80, sodium and potassium lactate, sodium benzoate, the off-note blocker may be added to suppress the bitterness associated with said preservatives.

- 10 In consumables containing zinc and other mineral supplements, the off-note blocker may be added to suppress the bitterness and metallic off-notes associated with said these mineral supplements.

- 15 In consumables containing mint oil or menthol (e.g. D-menthol) and citric acid of above 7%, the off-note blocker may be added to suppress the bitterness associated with this combination of ingredients.

In consumables containing quinine, the off-note blocker may be added to suppress the bitterness associated with quinine.

- 20 In consumables containing artificial sweeteners (e.g. aspartame, saccharin, acesulfameK, sucralose, cyclamate), for example beverages, a off-note blocker may be added to suppress the bitterness associated with artificial sweeteners.

- 25 In chewing gums, particular dental-type chewing gums, the off-note blocker may be added to suppress the bitterness associated with urea contained in chewing gums.

In consumables containing essential oils (e.g. thyme, sage, basil, mint), the off-note blocker may be added to suppress the bitterness associated with these essential oils.

- 30 In consumables containing vegetables or herbs or their extracts, the off-note blocker may be added to suppress the bitterness associated with these ingredients.

- 35 In consumables containing Maillard reaction products (i.e. cyclic amines made from proline/sucrose or alanine/xylose, e.g. diketopiperazines), the off-note blocker may be added to suppress the bitterness associated with Maillard reaction products.

In beer and consumables containing beer or hops, the off-note blocker may be added to suppress the bitterness associated with hops.

EXAMPLES

5

The following examples are set forth to describe the off-note blocking compounds in further detail and to illustrate the methods of employing the off-note blocking compounds to block or otherwise mask off-notes in consumables. The examples are illustrative and should not be construed as limiting the compounds, consumables or methods in any manner.

Example 1

Sensorial evaluation in various consumables

Off-note blockers as herein described are tested by panels of 6 to 10 bitter sensitive panelists.

Panelists are asked to describe the differences in off-notes and bitter notes between the product with 0.001% (wt/wt) off-note blocker unless otherwise stated and a control without off-note blocker.

A) Aspartame/Acesulfame-K containing Diet Energy Drink

The diet energy drink contained taurin, acesulfame K, aspartame, sucralose, glucuronolacton, caffeine, B-group vitamins (Niacin, pantothenic acid, B6, B12), aroma, sucrose, glucose, colours

The sample containing the off-note blocker is found to be less bitter compared to the control.

B) Sucrose/glucose-sweetened energy drink

The diet energy drink contains taurin, glucuronolacton, caffeine, B-group vitamins (Niacin, pantothenic acid, B6, B12), aroma, sucrose, glucose, colours.

The sample containing the off-note blocker is found to have less off-notes, to be less bitter, and less astringent compared to the control.

5 C) Iced low-sugar coffee

The sample containing the off-note blocker is found to be less bitter, and less astringent compared to the control.

10

D) Commercial Vanilla Flavored Nutritional Drink

Vanilla flavored nutritional drink containing calcium caseinate, soy protein isolate, sodium caseinate, vitamins and minerals.

15

The sample containing the off-note blocker is found to be less chalky, to have reduced protein/vitamin induced off-notes notes, and to be less astringent compared to control.

20 E) Saccharin sweetened cola soft drink

The sample containing the off-note blocker is found to be less bitter and to have a reduced after taste compared to the control.

25 F) Loperamide containing mint-flavored pharmaceutical syrup

The syrup contained 1 mg loperamide HCl per 7.5 ml serving. The off-note blocker is used in a concentration of 0.004% (wt/wt).

30 The sample containing the off-note blocker is found to be less bitter with especially the lingering bitter after taste reduced.

G) Daytime cough syrup

35 The daytime cough syrup contains 325 mg acetaminophen, 10 mg dextromethorphan HBr, 5 mg phenylephrine HCl per 15 ml serving.

The sample containing the off-note blocker is found to be less bitter.

H) Dark chocolate

5...

The sample containing the off-note blocker is found to be less bitter.

I) Baking Chocolate (100% Cocoa, Unsweetened)

10

The off-note blocker is used in a concentration of 0.002% (wt/wt).

The sample containing the off-note blocker is found to be less metallic, less bitter, especially the alkaloid/caffeine-like bitterness is reduced while the upfront, warm, woody bitterness was retained.

15

J) Overcooked coffee

Coffee is brewed and cooked on a burner for 3 hours. The off-note blocker is used in a concentration of 0.0005% (wt/wt).

20

The sample containing the off-note blocker is found to be less bitter.

K) Aspartame/Acesulfame-K sweetened plain nonfat yoghurt

25

The yoghurt contained 0.0193% (wt/wt) and acesulfame-K 0.0083% (wt/wt).

The off-note blocker is used in a concentration of 0.00175 % (wt/wt).

30

The sample containing the off-note blocker is found to have less off-notes compared to control.

L) Aspartame/Acesulfame-K sweetened cola soft drink

35

The off-note blocker is used in a concentration of 0.0063% (wt/wt).

<u>Cola soft drink</u>	<u>% (by weight)</u>
Sodium Benzoate	0.026
Aspartame	0.043
Acesulfame-K	0.017
Caffeine	0.011
Phosphoric Acid (85%)	0.043
Citric Acid (50% cut in water)	0.017
Caramel Color	0.085
Water	Balance to 100

The sample containing the off-note blocker is found to have less off-notes than the control.

5

M) Sucralose sweetened cola soft drink

The off-note blocker is used in a concentration of 0.0035% (wt/wt).

<u>sucralose cola soft drink</u>	<u>% (by weight)</u>
Sodium Benzoate	0.03
Sucralose (25% cut in water)	0.06
Caffeine	0.01
Phosphoric Acid (85%)	0.08
Caramel Color	0.09
Water	Balance to 100


10

The sample containing the off-note blocker is found to have less off-notes and be less bitter than the control.

15

Examples 2a-2xySynthesis of off-note blocking compoundsExample 2a5 Synthesis of 4-(2,2,3-trimethylcyclopentyl)butanoic acid:

4-(2,2,3-trimethylcyclopentyl)butanoic acid was synthesized in three steps; the first step reacts 2-(2,2,3-trimethylcyclopent-3-en-1-yl)acetaldehyde (aka campholenic aldehyde) to ethyl 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoate, in the second step the latter was subjected to a hydrogenation procedure to form ethyl 4-(2,2,3-trimethylcyclopentyl)butanoate, and in the third step, from the latter, 4-(2,2,3-trimethylcyclopentyl)butanoic acid was formed in presence of sodium hydroxide (NaOH) and tetrahydrofuran (THF).



15

Step 1 (formation of ethyl 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoate):

To a flame-dried 250 ml round bottom flask campholenic aldehyde (10.0 g, 65.7 mmol) and methyl tertiary-butyl ether (MTBE) (100 ml) were added to give a solution and the flask was slowly cooled to 0° C in an ice water bath. (Carbethoxymethylene)triphenyl-phosphorane (22.8 g, 66.0 mmol) was slowly added to the solution. The reaction mixture was stirred at 0° C for 20 min then stirred at room temperature for about 24 h. After the reaction was completed, the reaction mixture was reduced to half its volume *in vacuo* and 100 ml of hexanes was added. The flask containing the reaction mixture and hexanes was then placed in an ice bath for 30 min. The reaction mixture was then filtered through a plug of filter paper, celite,

25

silica, and sand and washed three times, first with hexanes, then 9:1 and then 1:1 Hexanes/MTBE. The combined eluates were concentrated *in vacuo* and purified via flash column chromatography (1:8 Hexanes/ Ethyl Acetate (AcOEt)) to give ethyl 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoate (13.1 g, 89%) as an oil. The NMR data is indicated below.

^1H NMR (300 MHz, CDCl_3) δ 6.92 (dd, $J = 10.5, 7.5$ Hz, 1H), 5.79 (d, $J = 15.6$ Hz, 1H), 5.13 (s, 1H), 4.13 (m, 2H), 2.3 (m, 2H), 2.1 (m, 1H), 1.8 (m, 2H), 1.52 (s, 3H), 1.24 (t, $J = 15$, 3H), 0.91 (s, 3H), 0.71 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 166.1, 148.6, 147.8, 121.5, 121.3, 59.6, 48.9, 46.2, 35.2, 32.9, 25.5, 19.5, 14.0, 12.2; MS m/z 222.

Step 2 - Hydrogenation procedure:

To a three necked round bottom flask with a stir bar flushed with nitrogen, Degussa type palladium on charcoal Pd/C (1.5 g, 10%Pd) was added as catalyst. The catalyst was covered with distilled water (8 ml) and ethyl 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoate/ethyl 4-(2,2,3-trimethylcyclopentyl)butanoic acid (10.0 g, 44.9 mmol) in Ethyl Acetate (AcOEt) (200 ml) was added to the reaction flask. The flask was flushed with hydrogen and the reaction was run under hydrogen balloons that were refilled as needed. After 17 h at room temperature the reaction was found to be completed by gas chromatography and mass spectrometry (GCMS). The reaction mixture was filtered through a celite plug. The organic layers were concentrated *in vacuo* and purified via flash column chromatography AcOEt/ Hexanes (gradient 0 to 40 %) to give ethyl 4-(2,2,3-trimethylcyclopentyl)butanoate/ethyl 4-(2,2,3-trimethylcyclopentyl)butanoic acid as a colorless oil (7.48 g, 74%). The NMR data is indicated below.

¹H NMR (300 MHz, CDCl₃) δ 4.18 (q, *J* = 7.14, 2H), 2.34 (m, 2H), 1.82 (m, 3H), 1.56 (m, 5H), 1.30 (t, *J* = 7.2, 3H), 0. (m, 2H), 0.99 (s, 3H), 0.86 (d, *J* = 5.4, 2H), 0.52 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 173.8, 60.1, 50.6, 45.2, 42.2, 34.8, 30.1, 30.0, 28.1, 25.6, 24.3, 14.3, 14.2, 13.8; MS *m/z* 226.

5

Step 3 – Saponification reaction

Ethyl 4-(2,2,3-trimethylcyclopentyl)butanoate (5 g, 22 mmol) was added to THF (25 ml) into a round bottom flask. Aqueous 1 N NaOH (25 ml) was then added to the flask and the reaction mixture was refluxed at 110° C for 8 h. Upon completion of the reaction, the reaction mixture was diluted with 1 N NaOH (25 ml) and the aqueous layer washed twice with MTBE (50 ml x 2). The aqueous layer was treated with aqueous 1.0 N HCl until it reached a pH of about 3 (for example from 2 to 4), then extracted three times with AcOEt (50 ml x 3). The combined AcOEt extracts were concentrated *in vacuo* and purified via flash column chromatography with (0-40% gradient) to give 4-(2,2,3-trimethylcyclopentyl)butanoic acid as a colorless oil (3.82 g, 87%). The NMR data is indicated below.


¹H NMR (300 MHz, CDCl₃) δ 11.22 (br s, 1H), 2.37 (m, 2H), 1.75 (m, 3H), 1.49 (m, 4H), 1.17 (m, 3H), 0.86 (s, 3H), 0.84 (d, *J* = 6.9 Hz, 3H), 0.52 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 179.9, 50.6, 45.2, 42.2, 34.4, 30.1, 30.0, 28.1, 25.0, 24.0, 14.3, 13.8; MS *m/z* 198.

Example 2b

Synthesis of 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid:

4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid was synthesized in two steps; the first step reacts campholenic aldehyde to ethyl 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoate as described herein-above, and in the second step, from the latter, 4-(2,2,3-

trimethylcyclopent-3-enyl)but-2-enoic acid was formed in presence of NaOH and THF (see reaction below).



- 5 Ethyl 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoate (2.0 g, 9.0 mmol) was added to THF (10 ml) in a 50 ml round bottom flask. Aqueous 1 N NaOH (10 ml) was then added to the flask and the reaction mixture was refluxed at 83° C for 19 h. Upon completion of the reaction, the reaction mixture was diluted with 1 N NaOH (10 ml) and the aqueous layer was washed twice with MTBE (10 ml x 2). The aqueous layer
- 10 was treated with aqueous 1.0 N HCl until it reached a pH of about 3 (for example from 2 to 4), then extracted three times with AcOEt (10 ml x 3). The combined AcOEt extracts were concentrated *in vacuo* and purified via flash column chromatography with MTBE/Hexanes (5-20% gradient) to give 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid (1.58 g) as a viscous oil (1.58 g, 90%). The NMR data is indicated
- 15 below.

¹H NMR (300 MHz, CDCl₃) δ 11.47 (br. s, 1H), 7.15 (m, 1H), 5.90 (d, *J* = 2.8 Hz 1H), 5.23 (s, 1H), 2.39 (m, 3H), 1.91 (m, 2H), 1.62 (s, 3H), 1.20 (s, 3H), 0.827 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 171.3, 152.2, 148.3, 121.9, 120.9, 49.1, 46.9, 35.4, 33.4, 25.8, 19.7, 12.5; MS *m/z* 194.

20


Example 2c

Synthesis of 4-(2,2,6-trimethylcyclohexyl)butanoic acid:

- 25 4-(2,2,6-trimethylcyclohexyl)butanoic acid was synthesized in three steps starting from 2-(2,6,6-trimethylcyclohex-1-enyl)acetaldehyde, analogous to the 3-step

procedure described for 4-(2,2,3-trimethylcyclopentyl)butanoic acid herein-above, with the exception that AcOEt was replaced by methanol (MeOH) in step 2, as indicated below.

The first step forms (E)-ethyl 4-(2,6,6-trimethylcyclohex-1-enyl)but-2-enoate, the second step forms ethyl 4-(2,2,6-trimethylcyclohexyl)butanoate, the third forms 4-(2,2,6-trimethylcyclohexyl)butanoic acid. The majority of the product comprises (E)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid), and (Z)-4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid) is present in a concentration of up to 10% (w/w) in the isomeric mixture.




Example 2d

15 Synthesis of 3-(2,2,6-trimethylcyclohexyl)propanoic acid

3-(2,2,6-trimethylcyclohexyl)propanoic acid was synthesized in three steps starting from 2,6,6-trimethylcyclohex-1-enecarbaldehyde, analogous to the 3-step procedure described for 4-(2,2,6-trimethylcyclohexyl)butanoic acid and 4-(2,2,3-trimethylcyclopentyl)butanoic acid herein-above, as indicated below.

The first step formed (E)-ethyl 3-(2,6,6-trimethylcyclohex-1-enyl)acrylate, the second step formed ethyl 3-(2,2,6-trimethylcyclohexyl)propanoate, the third formed the product 3-(2,2,6-trimethylcyclohexyl)propanoic acid.



Example 3

5 TAS2R44 bitter taste receptor assay for IC₅₀ determination

1) Generation of human TAS2R44 expression vector

The full length gene of human TAS2R44 was amplified by polymerase chain reaction (PCR) using gene-specific primers that span the entire coding region as described in
 10 WO 2004/029087.

The TAS2R44 cDNA was subcloned into an expression cassette based on either of the following plasmids/expression vectors: pcDNA3.1Zeo (Invitrogen). These vectors contain within their multiple cloning sites the nucleotide sequence coding for the first
 15 45 amino acids of the rat somatostatin receptor subtype 3 (RSS tag) to facilitate cell surface targeting of the transgene (SEQ ID #4) and the nucleotide sequence coding for the herpes simplex virus (HSV) glycoprotein D epitope (HSV epitope in aminoterminal to carboxyterminal direction, HSV tag). (SEQ ID #3) for facilitating immunocytochemical detection.

20 The TAS2R44 construct contains RSS tag, TAS2R44, and the HSV tag which are fused in frame to allow translation into the receptor protein and the resulting receptor cDNA.

25 This transfected expression vector is called pcDNA3.1Zeo-TAS2R44 (SEQ ID # 1) and allows for expression of the TAS2R44 protein (SEQ ID #2).

2) Generation of a cell line stably expressing Gα16-gustducin44 and TAS2R44

A cell line that stably expresses the human bitter taste receptor (TAS2R44) was generated by transfecting pcDNA3.1Zeo-TAS2R44 into HEK293T/Gα16-gustducin 44 cells (both formed as described in under 1) above. The host cell line HEK-293T is commercially available from the American Tissue Culture Collection (catalog #CRL-
5 1573).

Transfection was performed as follows:

On day 0, the HEK293T Gα16-gustducin44 cells were seeded in a 6-well plate at a density of 900,000 cells per well and grown over night in selective growth medium
10 (DMEM with 10% (v/v) heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, 100 µg/ml streptomycin, 200 µg/ml G418 and 200 µg/ml zeocin).

On day 1, the medium was exchanged with 2 ml of antibiotic-free and serum-free growth medium. 10 µl Lipofectamine 2000 was dissolved in 250 µl DMEM and incubated for 5 minutes at room temperature. In parallel, 4 µg TAS2R44 vector DNA
15 were dissolved in 250 µl DMEM. These two resulting solutions are mixed and incubated for 20 minutes at room temperature before they are added to the cells into the cell culture medium. After 4 hours, the medium is replaced with antibiotic-free, serum-containing growth medium.

The cells were incubated in humidified atmosphere (37 °C, 5% CO₂).

20 After 24 hours, the cells were re-plated in selective growth medium and were further incubated in a humidified atmosphere (37 °C, 5% CO₂).

After 2 to 4 weeks of culture (replacing medium as necessary), zeocin-resistant colonies were selected and expanded.

The selected clone was tested successfully for functional expression of TAS2R44.

25

3) Fluo-4 Calcium Assay

Fluo-4 AM (Invitrogen) is a fluorescent indicator of intracellular calcium dynamics (change in concentration) and allows monitoring changes in the calcium
30 concentration, particularly an increase in response to receptor activation occurring after agonist exposure.

At day 0, the HEK293T cell line stably expressing Gα16-gustducin44 and TAS2R44 formed as described under 2) was seeded in antibiotic-free growth medium (standard
35 DMEM with 10% (v/v) heat-inactivated fetal bovine serum, 2 mM L-glutamine standard DMEM with 10% (v/v) heat-inactivated fetal bovine serum, 2 mM L-

glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin) into black wall/clear bottom 96-well plates, coated with poly(ethylenimine) (0.005% v/v) at a concentration of 15,000 cells per well and incubated for 48 hours in humidified atmosphere (37 °C, 5% CO₂).

5

At the time of the assay, the growth medium was discarded and the cells were further incubated in a humidified atmosphere (37 °C, 5% CO₂) for 1 hour with 50 µl of loading buffer consisting of 1.5 µM Fluo-4 AM and 2.5 µM probenecid (Sigma-Aldrich) in DMEM.

10

Afterwards, the 96-well plate was washed 5 times with 200 µl of assay buffer (130 mM NaCl, 5 mM KCl, 10 mM HEPES, 2 mM CaCl₂, and 5 mM dextrose, pH 7.4) per well, using an automated plate washer (BioTek). The plate was further incubated for 30 minutes at room temperature in the dark to allow for complete de-esterification of the Fluo-4. Afterwards the plate was washed 5 times with 200 µl of assay buffer per well, and reconstituted with 180 µl of assay buffer per well.

15

For assay reading, the plate was placed in a Fluorometric Imaging Plate Reader (FLIPR) (FLIPR-TETRA™, Molecular Devices), and receptor activation was initiated by addition of 20 µl of a tenfold concentrated agonist stock solution (to give the desired agonist end concentration when added to the 180 microliter assay buffer volume), which was prepared in assay buffer.

20

Fluorescence was continuously monitored for 20 seconds to give a signal baseline (averaged to give F₀) prior to agonist addition and for 120 seconds after agonist addition. The change in signal divided by F₀ gives ΔF/F₀ indicated in the table, with ΔF being the maximum signal occurring within the 120 seconds minus the minimum signal (occurring within the 120 seconds after agonist addition).

25

All data was collected from at least two independent experiments each carried out in triplicate.

30

A concentration-response analysis was performed and IC₅₀ values were calculated by nonlinear regression using the function $f(x) = (a-d)/(1+(x/C)^{nh}) + d$; with a = minimum signal, d = maximum signal, nh = hill coefficient, C = IC₅₀, and x = antagonist concentration. IC₅₀ is the molar concentration of an antagonist which

35

produces 50% of the maximum possible effective/inhibitory response for that antagonist. A more potent antagonist will have a lower IC_{50} value.

5 The obtained calcium signals were corrected for the response of cells expressing only the G Protein α subunit ($G\alpha_{16}$ -gustducin44) and normalized to the fluorescence of cells prior to the stimulus using $\Delta F/F_0$ ($F_{max}-F_{min}/F_0$).

Example 4

10 Determination of IC_{50} of off-note blockers, saccharin

The following off-note blockers were tested: 4-(2,2,3-trimethylcyclopentyl)butanoic acid, 4-(2,2,6-trimethylcyclohexyl)butanoic acid, 3-(2,2,6-trimethylcyclohexyl)propanoic acid, 2-(3,4-dimethylcyclohexyl)acetic acid, 2-methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid, and 1-methyl-2-((1,2,2-trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid.

The method was performed as described in example 3, using saccharin as agonist. The cells are exposed to a constant concentration of saccharin (0.5 mM) and to a set of different concentrations of the off-note blocker. A fluo-4 calcium assay was
20 performed as described above in example 3 and gave an IC_{50} [micro molar] within the range of 0.05 to 25.

This means that the off-note blockers inhibited the response of the TAS2R44 bitter taste receptor and will be useful to block bitter taste.

25

Example 5

Determination of IC_{50} for off-note blockers, Acesulfame K

The method was performed as described in example 4, exchanging saccharin for
30 Acesulfame K (0.8 mM) as agonist. An IC_{50} within the same range was determined. This means that the off-note blockers inhibited the response of the TAS2R44 bitter taste receptor and will be useful to block bitter taste.

35 Example 6

Determination of IC_{50} for off-note blockers, sucralose

The method was performed testing 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid as described in example 4, exchanging saccharin for sucralose (50 mM) as agonist. An IC_{50} within the same range was determined. This means that the off-note blockers inhibited the response of the TAS2R44 bitter taste receptor and will be
5 useful to block bitter taste.

Example 7

Sensory evaluation of 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid.

10

The bitter blocker (13 ppm) was tested in water with sucralose in concentrations of 1mM, 3mM, and 7mM by a panel of bitter sensitive individuals (15) in two replications per each concentration. The samples were compared to negative controls without bitter blocker and panelists were instructed to choose the less bitter sample in a
15 forced choice test.

The bitter blocker was found to significantly reduce bitterness (22/30 panelists chose the sample with bitter blocker as less bitter).

20 The sequences employed in the constructs and methods described-herein can be found in the sequence listing herein-below.

While the compounds, consumable and methods have been described above in connection with illustrative embodiments, it is to be understood that other similar
25 embodiments may be used or modifications and additions may be made to the described embodiments for performing the same function without deviating therefrom. Further, all embodiments disclosed are not necessarily in the alternative, as various embodiments of the invention may be combined to provide the desired characteristics. Variations can be made by one having ordinary skill in the art without
30 departing from the spirit and scope of the invention. Therefore, the compounds, consumables and methods should not be limited to any single embodiment, but rather construed in breadth and scope in accordance with the recitation of the attached claims.

Claims:

1. An off-note blocking compound selected from one or more of
4-(2,2,3-trimethylcyclopent-3-enyl)but-2-enoic acid, 4-(2,2,3-
5 trimethylcyclopentyl)butanoic acid, 4-(2,2,6-trimethylcyclohexyl)butanoic acid, 3-
(2,2,6-trimethylcyclohexyl)propanoic acid, 2-(3,4-dimethylcyclohexyl)acetic acid, 2-
methyl-4-(2,6,6-trimethylcyclohex-2-enyl)butanoic acid, 1-methyl-2-((1,2,2-
trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid;
(E)-3-(1-(2,2,3-trimethylcyclopent-3-enyl)cyclopropyl)acrylic acid, (E)-4-(2,2,3-
10 trimethylcyclohex-3-enyl)but-2-enoic acid, (E)-4-(2,2,3-trimethylcyclopentyl)but-3-
enoic acid, (E)-4-(2,2,3-trimethylcyclopentyl)but-2-enoic acid, 1-methyl-2-((1,2,2-
trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropanecarboxylic acid, 2,2-dimethyl-4-
(2,2,3-trimethylcyclopentyl)butanoic acid, 2-((1,4-dimethylbicyclo[3.1.0]hexan-2-
yl)methyl)-1-methylcyclopropanecarboxylic acid, 2-(1-((1,2,2-
15 trimethylbicyclo[3.1.0]hexan-3-yl)methyl)cyclopropyl)propanoic acid, 2-(1-((1-
methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid, 3,3-dimethyl-4-(2,2,3-
trimethylcyclopentyl)butanoic acid, and 4-(1-methylbicyclo[3.1.0]hexan-2-yl)butanoic
acid, (E)-1-(2-(1-methylbicyclo[3.1.0]hexan-2-yl)vinyl)cyclopropanecarboxylic acid,
(E)-1-(2-(7-methylspiro[2.4]heptan-4-yl)vinyl)cyclopropanecarboxylic acid, (E)-4-(1-
20 methylbicyclo[3.1.0]hexan-2-yl)but-3-enoic acid, (E)-4-(7-methylspiro[2.4]hept-6-en-
4-yl)but-2-enoic acid, (E)-4-(7-methylspiro[2.4]heptan-4-yl)but-3-enoic acid, (E)-4-(7-
methylspiro[2.4]heptan-4-yl)but-2-enoic acid, (E)-4-(8-methylspiro[2.5]oct-7-en-4-
yl)but-2-enoic acid, 1-(2-(7-methylspiro[2.4]heptan-4-yl)ethyl)cyclopropanecarboxylic
acid, 2-((6,7-dimethylspiro[2.4]heptan-4-yl)methyl)-1-methylcyclopropanecarboxylic
25 acid, 2-(1-((1,4-dimethylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)propanoic acid,
2-(1-((1-methylbicyclo[3.1.0]hexan-2-yl)methyl)cyclopropyl)acetic acid, 2-(1-(7-
methylspiro[2.4]heptan-4-yl)methyl)cyclopropyl)acetic acid, and 4-(7-
methylspiro[2.4]heptan-4-yl)butanoic acid.
- 30 2. The off-note blocking compound of claim 1, selected from the group consisting of
4-(2,2,3-trimethylcyclopentyl)butanoic acid, 4-(2,2,3-trimethylcyclopent-3-enyl)but-2-
enoic acid, 4-(2,2,6-trimethylcyclohexyl)butanoic acid, 3-(2,2,6-
trimethylcyclohexyl)propanoic acid, 4-propylcyclohexanecarboxylic acid, 2-(3,4-
dimethylcyclohexyl)acetic acid and mixtures thereof.

3. A flavor composition comprising an off-note providing consumable ingredient and one or more off-note blocking compound as defined in claim 1 or 2.
4. A consumable comprising
- 5 a) one or more ingredient in a concentration sufficient to provide an off-note, and
- b) one or more off-note blocking compound as defined in claim 1 or 2.
5. The consumable of claim 4, wherein the one or more off-note providing
- 10 ingredient is selected from the group consisting of sweetener, artificial sweetener, beverage, chewing gum, nutraceutical, and pharmaceutical.
6. The consumable of claim 4, wherein the one or more off-note providing ingredient comprises an artificial sweetener selected from the group consisting of
- 15 aspartame, Acesulfame K, saccharin, sucralose, sodium cyclamate and mixtures thereof.
7. The consumable of claim 4, wherein the one or more off-note providing ingredient comprises a sweetener selected from the group consisting of including
- 20 stevioside, swingle extract, glycyrrhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, rebaudioside A and mixtures thereof.
8. The consumable of claim 4, wherein the one or more off-note providing
- 25 ingredient comprises a consumable selected from the group consisting of cocoa, coffee, caffeine, theobromine, diketopiperazines, vitamins, amino acids, vitamin B, casein, soy protein, ibuprofen, salicylic acid, glucoronolactone, acetaminophen, dextromethorphan, naringin, taurin, macrolide (including bioxin and erythromycin), paracetamol, acetylsalicylic acid, cimetidine, ranitidine, amoxicillin, acetaminophen,
- 30 cephalosporines, quassia, propylene glycol, triacetin, potassium, zinc, loperamide, limonin, flavonoides, isoflavones (including genistein and diadzein), polyphenol (including catechin and epicatechin), mint oil, D-menthol, hydrolysed vegetable protein, bitter peptides, preservatives (including benzoic acid, potassium sorbate, polysorbate 80, sodium and potassium lactate, sodium benzoate), citric acid, quinine,
- 35 urea (contained in chewing gums), essential oils (including thyme, sage, basil, mint), Maillard reaction products (including cyclic amines made from pyrrolidine/glucose,

alanine/xylose, proline/sucrose or alanine/xylose, for example diketopiperazines), beer, hops, humulone, trans-isohumulone, lupulone, hulupone and mixtures thereof.

9. A method of blocking off-notes in consumables comprising: admixing with the consumable (a) one or more off-note providing ingredient in a concentration sufficient to provide an off-note, and (b) one or more off-note blocking compound as defined in claim 1 and 2.
10. The method of claim 9, wherein the one or more off-note providing ingredient is selected from the group consisting of sweetener, artificial sweetener, beverage, chewing gum, nutraceutical, and pharmaceutical.
11. The method of claim 9, wherein the one or more off-note providing ingredient comprises an artificial sweetener selected from the group consisting of aspartame, acesulfame K, saccharin, sucralose, sodium cyclamate and mixtures thereof.
12. The method of claim 9, wherein the one or more off-note providing ingredient comprises a sweetener selected from the group consisting of including stevioside, swingle extract, glycyrrhizin, perillartine, naringin dihydrochalcone, neohesperidine dihydrochalcone, mogroside V, rubusoside, rubus extract, rebaudioside A and mixtures thereof.
13. The method of claim 9, wherein the one or more off-note providing ingredient comprises a consumable selected from the group consisting of cocoa, coffee, caffeine, theobromine, diketopiperazines, vitamins, amino acids, vitamin B, casein, soy protein, ibuprofen, salicylic acid, glucoronolactone, acetaminophen, dextromethorphan, naringin, taurin, macrolide (including bioxin and erythromycin), paracetamol, acetosalicylic acid, cimetidine, ranitidine, amoxicillin, acetaminophen, cephalosporines, quassia, propylene glycol, triacetin, potassium, zinc, loperamide, limonin, flavonoides, isoflavones (including genistein and diadzein), polyphenol (including catechin and epicatechin), mint oil, D-menthol, hydrolysed vegetable protein, bitter peptides, preservatives (including benzoic acid, potassium sorbate, polysorbate 80, sodium and potassium lactate, sodium benzoate), citric acid, quinine, urea (contained in chewing gums), essential oils (including thyme, sage, basil, mint), Maillard reaction products (including cyclic amines made from pyrrolidine/glucose,

alanine/xylose, proline/sucrose or alanine/xylose, for example diketopiperazines), beer, hops, humulone, trans-isohumulone, lupulone, hulupone and mixtures thereof.

30310_PCT_sequences.ST25.txt
SEQUENCE LISTING

<110> Givaudan SA
 <120> Organic compounds
 <130> 30310/PCT
 <160> 4
 <170> PatentIn version 3.3
 <210> 1
 <211> 1113
 <212> DNA
 <213> Artificial
 <220>
 <223> artificial DNA

<220>
 <221> CDS
 <222> (1)..(1113)

<400> 1
 atg gcc gct gtt acc tat cct tca tcc gtg cct acg acc ttg gac cct 48
 Met Ala Ala Val Thr Tyr Pro Ser Ser Val Pro Thr Thr Leu Asp Pro
 1 5 10
 ggg aat gca tcc tca gcc tgg ccc ctg gac acg tcc ctg ggg aat gca 96
 Gly Asn Ala Ser Ser Ala Trp Pro Leu Asp Thr Ser Leu Gly Asn Ala
 20 25 30
 tct gct ggc act agc ctg gca gga ctg gct gtc agt ggc gaa ttc atg 144
 Ser Ala Gly Thr Ser Leu Ala Gly Leu Ala Val Ser Gly Glu Phe Met
 35 40 45
 aca act ttt ata ccc atc att ttt tcc agt gtg gta gtg gtt cta ttt 192
 Thr Thr Phe Ile Pro Ile Ile Phe Ser Ser Val Val Val Val Leu Phe
 50 55 60
 gtt att gga aat ttt gct aat ggc ttc ata gca ttg gta aat tcc att 240
 Val Ile Gly Asn Phe Ala Asn Gly Phe Ile Ala Leu Val Asn Ser Ile
 65 70 75 80
 gag cgg gtc aag aga caa aag atc tct ttt gct gac cag att ctc act 288
 Glu Arg Val Lys Arg Gln Lys Ile Ser Phe Ala Asp Gln Ile Leu Thr
 85 90 95
 gct ctg gcg gtc tcc aga gtt ggt ttg ctc tgg gta tta tta tta aat 336
 Ala Leu Ala Val Ser Arg Val Gly Leu Leu Trp Val Leu Leu Leu Asn
 100 105 110
 tgg tat tca act gtg ttt aat cca gct ttt tat agt gta gaa gta aga 384
 Trp Tyr Ser Thr Val Phe Asn Pro Ala Phe Tyr Ser Val Glu Val Arg
 115 120 125
 act act gct tat aat gtc tgg gca gta acc ggc cat ttc agc aac tgg 432
 Thr Thr Ala Tyr Asn Val Trp Ala Val Thr Gly His Phe Ser Asn Trp
 130 135 140
 ctt gct act agc ctc agc ata ttt tat ttg ctc aag att gcc aat ttc 480
 Leu Ala Thr Ser Leu Ser Ile Phe Tyr Leu Leu Lys Ile Ala Asn Phe
 145 150 155 160
 tcc aac ctt att ttt ctt cac tta aag agg aga gtt aag agt gtc att 528
 Ser Asn Leu Ile Phe Leu His Leu Lys Arg Arg Val Lys Ser Val Ile

30310_PCT_sequences.ST25.txt

										165											170											175	
ctg	gtg	atg	ctg	ttg	ggg	cct	tta	cta	ttt	ttg	gct	tgt	caa	ctt	ttt		576																
Leu	Val	Met	Leu	Leu	Gly	Pro	Leu	Leu	Phe	Leu	Ala	Cys	Gln	Leu	Phe																		
			180					185					190																				
gtg	ata	aac	atg	aaa	gag	att	gta	cgg	aca	aaa	gaa	tat	gaa	gga	aac		624																
Val	Ile	Asn	Met	Lys	Glu	Ile	Val	Arg	Thr	Lys	Glu	Tyr	Glu	Gly	Asn																		
		195					200					205																					
atg	act	tgg	aag	atc	aaa	ttg	agg	agt	gca	gtg	tac	ctt	tca	gat	gcg		672																
Met	Thr	Trp	Lys	Ile	Lys	Leu	Arg	Ser	Ala	Val	Tyr	Leu	Ser	Asp	Ala																		
	210					215					220																						
act	gta	acc	acg	cta	gga	aac	tta	gtg	ccc	ttc	act	ctg	acc	ctg	cta		720																
Thr	Val	Thr	Thr	Leu	Gly	Asn	Leu	Val	Pro	Phe	Thr	Leu	Thr	Leu	Leu																		
225					230					235					240																		
tgt	ttt	ttg	ctg	tta	atc	tgt	tct	ctg	tgt	aaa	cat	ctc	aag	aag	atg		768																
Cys	Phe	Leu	Leu	Leu	Ile	Cys	Ser	Leu	Cys	Lys	His	Leu	Lys	Lys	Met																		
				245					250					255																			
cag	ctc	cat	ggg	aaa	gga	tct	caa	gat	ccc	agc	acc	aag	gtc	cac	ata		816																
Gln	Leu	His	Gly	Lys	Gly	Ser	Gln	Asp	Pro	Ser	Thr	Lys	Val	His	Ile																		
			260					265					270																				
aaa	gct	ttg	caa	act	gtg	atc	ttt	ttc	ctc	ttg	tta	tgt	gcc	gtt	tac		864																
Lys	Ala	Leu	Gln	Thr	Val	Ile	Phe	Phe	Leu	Leu	Leu	Cys	Ala	Val	Tyr																		
		275					280					285																					
ttt	ctg	tcc	ata	atg	ata	tca	gtt	tgg	agt	ttt	ggg	agt	ctg	gaa	aac		912																
Phe	Leu	Ser	Ile	Met	Ile	Ser	Val	Trp	Ser	Phe	Gly	Ser	Leu	Glu	Asn																		
	290					295					300																						
aaa	cct	gtc	ttc	atg	ttc	tgc	aaa	gct	att	aga	ttc	agc	tat	cct	tca		960																
Lys	Pro	Val	Phe	Met	Phe	Cys	Lys	Ala	Ile	Arg	Phe	Ser	Tyr	Pro	Ser																		
305					310					315					320																		
atc	cac	cca	ttc	atc	ctg	att	tgg	gga	aac	aag	aag	cta	aag	cag	act		1008																
Ile	His	Pro	Phe	Ile	Leu	Ile	Trp	Gly	Asn	Lys	Lys	Leu	Lys	Gln	Thr																		
				325					330					335																			
ttt	ctt	tca	gtt	ttg	cgg	caa	gtg	agg	tac	tgg	gtg	aaa	gga	gag	aag		1056																
Phe	Leu	Ser	Val	Leu	Arg	Gln	Val	Arg	Tyr	Trp	Val	Lys	Gly	Glu	Lys																		
			340					345					350																				
cct	tca	tct	cca	tgc	ggc	cgc	cag	cct	gaa	ctc	gct	cct	gaa	gac	ccg		1104																
Pro	Ser	Ser	Pro	Cys	Gly	Arg	Gln	Pro	Glu	Leu	Ala	Pro	Glu	Asp	Pro																		
		355					360					365																					
gaa	gat	taa															1113																
Glu	Asp																																
	370																																

<210> 2
 <211> 370
 <212> PRT
 <213> Artificial

<220>
 <223> Synthetic Construct

<400> 2

Met Ala Ala Val Thr Tyr Pro Ser Ser Val Pro Thr Thr Leu Asp Pro
 1 5 10 15

30310_PCT_sequences.ST25.txt

Gly Asn Ala Ser Ser Ala Trp Pro Leu Asp Thr Ser Leu Gly Asn Ala
 20 25 30
 Ser Ala Gly Thr Ser Leu Ala Gly Leu Ala Val Ser Gly Glu Phe Met
 35 40 45
 Thr Thr Phe Ile Pro Ile Ile Phe Ser Ser Val Val Val Val Leu Phe
 50 55 60
 Val Ile Gly Asn Phe Ala Asn Gly Phe Ile Ala Leu Val Asn Ser Ile
 65 70 75 80
 Glu Arg Val Lys Arg Gln Lys Ile Ser Phe Ala Asp Gln Ile Leu Thr
 85 90 95
 Ala Leu Ala Val Ser Arg Val Gly Leu Leu Trp Val Leu Leu Leu Asn
 100 105 110
 Trp Tyr Ser Thr Val Phe Asn Pro Ala Phe Tyr Ser Val Glu Val Arg
 115 120 125
 Thr Thr Ala Tyr Asn Val Trp Ala Val Thr Gly His Phe Ser Asn Trp
 130 135 140
 Leu Ala Thr Ser Leu Ser Ile Phe Tyr Leu Leu Lys Ile Ala Asn Phe
 145 150 155 160
 Ser Asn Leu Ile Phe Leu His Leu Lys Arg Arg Val Lys Ser Val Ile
 165 170 175
 Leu Val Met Leu Leu Gly Pro Leu Leu Phe Leu Ala Cys Gln Leu Phe
 180 185 190
 Val Ile Asn Met Lys Glu Ile Val Arg Thr Lys Glu Tyr Glu Gly Asn
 195 200 205
 Met Thr Trp Lys Ile Lys Leu Arg Ser Ala Val Tyr Leu Ser Asp Ala
 210 215 220
 Thr Val Thr Thr Leu Gly Asn Leu Val Pro Phe Thr Leu Thr Leu Leu
 225 230 235 240
 Cys Phe Leu Leu Leu Ile Cys Ser Leu Cys Lys His Leu Lys Lys Met
 245 250 255
 Gln Leu His Gly Lys Gly Ser Gln Asp Pro Ser Thr Lys Val His Ile
 260 265 270
 Lys Ala Leu Gln Thr Val Ile Phe Phe Leu Leu Leu Cys Ala Val Tyr
 275 280 285

30310_PCT_sequences.ST25.txt

Phe Leu Ser Ile Met Ile Ser Val Trp Ser Phe Gly Ser Leu Glu Asn
 290 295 300

Lys Pro Val Phe Met Phe Cys Lys Ala Ile Arg Phe Ser Tyr Pro Ser
 305 310 315 320

Ile His Pro Phe Ile Leu Ile Trp Gly Asn Lys Lys Leu Lys Gln Thr
 325 330 335

Phe Leu Ser Val Leu Arg Gln Val Arg Tyr Trp Val Lys Gly Glu Lys
 340 345 350

Pro Ser Ser Pro Cys Gly Arg Gln Pro Glu Leu Ala Pro Glu Asp Pro
 355 360 365

Glu Asp
 370

<210> 3
 <211> 45
 <212> DNA
 <213> herpes simplex virus

<400> 3
 tgcggccgcc agcctgaact cgctcctgaa gacccggaag attaa 45

<210> 4
 <211> 144
 <212> DNA
 <213> rat

<400> 4
 atggccgctg ttacctatcc ttcatccgtg cctacgacct tggaccctgg gaatgcatcc 60
 tcagcctggc ccctggacac gtccctgggg aatgcatctg ctggcactag cctggcagga 120
 ctggctgtca gtggcgaatt catg 144